Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on September 6, 2023. The filing addresses a modification to the appointment terms of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change reported is the acceleration of the effective date for Howard Horn's appointment as Chief Financial Officer and Executive Vice President, Corporate Strategy. The effective date was modified from October 16, 2023, to October 9, 2023. This change was formalized through Amendment No. 1 to the original offer letter dated June 22, 2023.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The document is limited to the administrative update regarding the executive's start date.
Key Facts for Investor Verification
- Howard Horn's start date as CFO and EVP, Corporate Strategy is now October 9, 2023.
- The change was executed via Amendment No. 1 dated September 6, 2023.
- The full text of the Offer Letter Amendment is filed as Exhibit 10.1.
- No financial results or operational metrics are disclosed in this specific filing.